Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC).

Vokes EE, Seiwert TY, Blair E, Cohen EE, Salama J, Villaflor VM, Witt M, Kovacevic M, Stenson K, Haraf D. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6067.

View in: PubMed